Drug Detox - Mushroom Compound - Microglia & Puberty - MS Vulnerability

[Breedlove, S]

https://www.nytimes.com/2026/05/06/health/synthetic-drug-detox-experiment.html

Her Self-Experiment with Drug Detox Almost Broke Her

By Matt Richtel

A 27-year-old woman began an experiment on herself early one morning in December 2024. Her laboratory was her childhood bedroom, tucked into a second-floor corner of a pale yellow house in the Boston suburbs. On a bookshelf behind her sat a small stuffed sloth and some favorite books, including “Siddhartha” by Hermann Hesse. Her parents were asleep in the room next door.

Her name is Rebecca, but she goes by Becks. Sitting at her desk in a gray T-shirt, she opened a small plastic bag filled with white powder. The bag was stamped “SR-17018,” and “NOT FOR HUMAN CONSUMPTION.”

She extracted some powder with a red microscooper, poured it onto a digital scale and carefully weighed out 25 milligrams. She gathered this into a blue and white pill capsule and sealed it, and then swallowed the capsule with water. It was 4:27 a.m.

“It’s my turn to be a guinea pig,” Becks wrote in the online diary she was keeping of her experience. In sharing her story with The New York Times, she asked that her last name not be used so potential employers don’t discover her drug history.

Becks had joined the vanguard of a dangerous, highly speculative do-it-yourself approach to getting sober. For a decade, on and off, she had been addicted to various drugs, most recently kratom, an opiate-like substance, which cleared her head and covered up her pain but required constant dosing. She feared the call of fentanyl, which she’d tried a few times.

“Every morning, I woke drenched in sweat from overnight withdrawals. It was a grim existence,” she wrote of her kratom use. She tried various methods to get sober, including three short inpatient detox stays and one monthlong rehabilitation treatment. She had periods of sobriety but couldn’t sustain it.

    © 2026 The New York Times Company


--------------------


https://www.science.org/content/article/magic-mushroom-compound-shows-promise-against-cocaine-addiction

Magic mushroom compound shows promise against cocaine addiction

 By Rachel Nuwer 

Despite billions of dollars spent on potential drug treatments for cocaine addiction, none have proved effective—and cocaine use is increasing in the United States and around the world. But one class of possible remedy has remained untested: psychedelics, which have shown promise for treating post-traumatic stress disorder, depression, anxiety, alcohol use disorder, smoking, and more.

Now, the results of a pioneering randomized trial—more than a decade in the making—reveal a single dose of psilocybin, the psychedelic component of magic mushrooms, brought significant relief for people addicted to cocaine. The study of 40 people, described today in JAMA Network Open, showed that 180 days after treatment, 30% of the psilocybin group was completely abstaining from cocaine, versus none of the placebo group—and those who continued using the drug did so less frequently.

“This is significantly better than any medication ever tested to treat cocaine use disorder,” says Stephen Ross, a professor of psychiatry at New York University who was not involved in the work. He called results “remarkable,” and the magnitude of the effects “highly substantial.”

The study, funded by the University of Alabama at Birmingham (UAB) and the nonprofit Heffter Research Institute, was also notable for its participant pool. Of the 40 people who took part, more than 80% were Black and 65% earned less than $20,000 a year. “Although the study was small, one strength is that most participants had lower than average income and education, which are associated with barriers to addiction treatment,” says Nora Volkow, director of the National Institute on Drug Abuse, who was not involved in the trial.

More research will be needed to replicate the findings, she says, but the study provides evidence “that psilocybin has promise for treating addiction to cocaine and potentially other illicit stimulants.”

© 2026 American Association for the Advancement of Science. 
--------------------


https://www.thetransmitter.org/microglia/microglia-in-hypothalamus-help-kick-start-puberty/

 Microglia in hypothalamus help kick-start puberty

By Helena Kudiabor

Microglia, known for scavenging debris and attacking pathogens, may also help regulate the hypothalamic-pituitary-gonadal axis, a new study shows. The findings, published in March in Science, suggest that microglia interact with and influence the function of hypothalamic neurons that release gonadotropin-releasing hormone (GnRH), which stimulates the pituitary to produce the hormones that spark ovulation and spermatogenesis. 

“One of the biggest surprises was the role of microglia in controlling the GnRH neurons, because this is a link that hadn’t been seen before,” says study investigator Alejandro Collado-Solé, a postdoctoral researcher in Eva González-Suárez’s group at the Spanish National Cancer Research Center. 

Microglia express a protein called RANK that is crucial to their effects on the hypothalamic-pituitary-gonadal axis. Knocking out RANK in mice reduces microglia’s interactions with GnRH neurons, lowers sex hormone levels and renders some of the animals infertile, the new study found.

“The fact that these specific interactions in such a small region of the brain can have such profound effects on fertility—a very fundamental aspect of the survival of a species—was quite unexpected,” says Annie Ciernia, assistant professor of biochemistry and molecular biology at the University of British Columbia, who was not involved in the research.

Microglia have been widely studied for their role in brain development, but the new study is the first to explore how these cells support the reproductive system.


© 2026 Simons Foundation

--------------------


https://www.sciencenews.org/article/brain-cells-multiple-sclerosis-dna

 Why some brain cells are particularly vulnerable to multiple sclerosis

By Alonso Daboub

Brain cells that help make us human are also uniquely vulnerable to multiple sclerosis.

A newfound cellular repair kit can’t keep up with the disease’s damage, leading to the cell death that’s a hallmark of progressive MS, researchers report April 1 in two papers in Nature.

The discovery uncovers an important and underexplored mechanism behind how the condition progressively shrinks the brain. By better understanding how MS kills brain cells, scientists can design treatments aimed at preventing cognitive decline, says David Rowitch, a developmental neuroscientist at the University of Cambridge.

Each year, 10,000 people in the United States are diagnosed with MS. The body’s immune system attacks neurons in the brain, causing inflammation and unpredictable flare-ups of muscle weakness, tingling and pain. Research has primarily focused on the way the disease causes nerve fibers to lose myelin, the fatty insulation that helps them send messages. But in a second, progressive phase, neurons in the brain begin to die. Patients experience sharper declines in their cognitive ability, leading to difficulties in memory and reasoning as their brains shrink.

“There’s no treatment really for that part,” says Steve Fancy, a neuroscientist at the University of California, San Francisco
Previous research identified a specific group of neurons in the human cortex, the brain’s wrinkly outermost layer, that are particularly vulnerable to degeneration in progressive MS. Called CUX2 neurons, these brain cells help make up two layers of the cortex thought to play an important role in things like cognition and computation. These layers in the brain are “really very important for making us human,” Fancy says.

© Society for Science & the Public 2000–2026.
--------------------